ZAI LAB LIMITED Research and Development Expense
ZAI LAB LIMITED (ZLAB) reported Research and Development Expense of $61.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ZAI LAB LIMITED research and development expense for the quarter ending 2026-06-30 was $61.77M, a 22.03% increase year-over-year.
- ZAI LAB LIMITED research and development expense for the quarter ending 2026-03-31 was $65.59M, a 8.01% increase year-over-year.
- ZAI LAB LIMITED research and development expense for the quarter ending 2025-12-31 was $61.63M, a 17.95% increase year-over-year.
- ZAI LAB LIMITED research and development expense for the quarter ending 2025-09-30 was $47.93M, a 27.36% decline year-over-year.
- ZAI LAB LIMITED research and development expense for fiscal 2025 was $220.90M, a 5.80% decline from fiscal 2024.
- ZAI LAB LIMITED research and development expense for fiscal 2024 was $234.50M, a 11.80% decline from fiscal 2023.
- ZAI LAB LIMITED research and development expense for fiscal 2023 was $265.87M, a 7.17% decline from fiscal 2022.
- ZAI LAB LIMITED research and development expense for fiscal 2022 was $286.41M, a 50.04% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $61.77M 10-Q · filed 2026-08-06 | $127.36M 10-Q · filed 2026-08-06 | $188.99M derived: sum of 3 quarters · filed 2026-08-06 | $236.92M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $65.59M 10-Q · filed 2026-05-07 | $127.22M derived: sum of 2 quarters · filed 2026-05-07 | $175.15M derived: sum of 3 quarters · filed 2026-05-07 | $225.77M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $61.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $109.56M derived: sum of 2 quarters · filed 2026-02-26 | $160.18M derived: sum of 3 quarters · filed 2026-08-06 | $220.90M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $47.93M 10-Q · filed 2025-11-06 | $98.54M derived: sum of 2 quarters · filed 2026-08-06 | $159.27M 10-Q · filed 2025-11-06 | $211.52M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $50.61M 10-Q · filed 2026-08-06 | $111.34M 10-Q · filed 2026-08-06 | $163.59M derived: sum of 3 quarters · filed 2026-08-06 | $229.58M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $60.73M 10-Q · filed 2026-05-07 | $112.98M derived: sum of 2 quarters · filed 2026-05-07 | $178.96M derived: sum of 3 quarters · filed 2026-05-07 | $240.59M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $52.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $118.23M derived: sum of 2 quarters · filed 2026-02-26 | $179.86M derived: sum of 3 quarters · filed 2026-02-26 | $234.50M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $65.98M 10-Q · filed 2025-11-06 | $127.61M derived: sum of 2 quarters · filed 2025-11-06 | $182.25M 10-Q · filed 2025-11-06 | $264.20M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $61.63M 10-Q · filed 2025-08-07 | $116.27M 10-Q · filed 2025-08-07 | $198.22M derived: sum of 3 quarters · filed 2026-02-26 | $256.99M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $54.65M 10-Q · filed 2025-05-08 | $136.59M derived: sum of 2 quarters · filed 2026-02-26 | $195.36M derived: sum of 3 quarters · filed 2026-02-26 | $272.04M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $81.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $140.72M derived: sum of 2 quarters · filed 2026-02-26 | $217.40M derived: sum of 3 quarters · filed 2026-02-26 | $265.87M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $58.77M 10-Q · filed 2024-11-12 | $135.45M derived: sum of 2 quarters · filed 2024-11-12 | $183.92M 10-Q · filed 2024-11-12 | $250.87M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $76.68M 10-Q · filed 2024-08-06 | $125.15M 10-Q · filed 2024-08-06 | $192.10M derived: sum of 3 quarters · filed 2025-02-27 | $291.62M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $48.47M 10-Q · filed 2024-05-08 | $115.42M derived: sum of 2 quarters · filed 2025-02-27 | $214.94M derived: sum of 3 quarters · filed 2025-02-27 | $281.03M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $66.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $166.47M derived: sum of 2 quarters · filed 2025-02-27 | $232.55M derived: sum of 3 quarters · filed 2025-02-27 | $286.41M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $99.52M 10-Q · filed 2023-11-07 | $165.61M derived: sum of 2 quarters · filed 2023-11-07 | $219.46M 10-Q · filed 2023-11-07 | $391.55M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $66.08M 10-Q · filed 2023-08-07 | $119.94M 10-Q · filed 2023-08-07 | $292.02M derived: sum of 3 quarters · filed 2024-02-27 | $347.17M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $53.85M 10-Q · filed 2023-05-09 | $225.94M derived: sum of 2 quarters · filed 2024-02-27 | $281.08M derived: sum of 3 quarters · filed 2024-02-27 | $423.31M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $172.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $227.23M derived: sum of 2 quarters · filed 2024-02-27 | $369.45M derived: sum of 3 quarters · filed 2024-02-27 | $573.31M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $55.14M 10-Q · filed 2022-11-09 | $197.37M derived: sum of 2 quarters · filed 2022-11-09 | $401.22M 10-Q · filed 2022-11-09 | $463.78M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $142.22M 10-Q · filed 2022-08-09 | $346.08M 10-Q · filed 2022-08-09 | $408.64M derived: sum of 3 quarters · filed 2023-03-01 | $466.74M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $203.85M 10-Q · filed 2022-05-10 | $266.41M derived: sum of 2 quarters · filed 2023-03-01 | $324.51M derived: sum of 3 quarters · filed 2023-03-01 | $392.82M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $62.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $120.66M derived: sum of 2 quarters · filed 2023-03-01 | $188.97M derived: sum of 3 quarters · filed 2023-03-01 | $222.71M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $58.10M 10-Q · filed 2021-11-09 | $126.41M derived: sum of 2 quarters · filed 2021-11-09 | $160.15M 10-Q · filed 2021-11-09 | $192.24M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $68.31M 10-Q · filed 2021-08-09 | $102.05M 10-Q · filed 2021-08-09 | $134.14M derived: sum of 3 quarters · filed 2022-03-01 | $185.34M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $33.74M 10-Q · filed 2021-05-10 | $65.84M derived: sum of 2 quarters · filed 2022-03-01 | $117.03M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $32.10M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $83.29M derived: sum of 2 quarters · filed 2022-03-01 | $142.22M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $51.20M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $110.13M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $58.93M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $55.65M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $120.28M 10-K · filed 2021-03-01 | $120.28M 20-F · filed 2019-03-29 | ||
| 2018-09-30 | $64.63M 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | $39.34M 20-F · filed 2020-04-29 | $39.34M 20-F · filed 2018-04-30 | |||
| 2016-12-31 | $32.15M 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | $13.59M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |